Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine (RPL554) DPI in COPD
NCT04027439Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Started Dec 2018; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04027439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027439.